Wounds – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Wounds – Pipeline Review, H1 2020’, provides an overview of the Wounds pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wounds, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wounds and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Wounds

– The report reviews pipeline therapeutics for Wounds by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Wounds therapeutics and enlists all their major and minor projects

– The report assesses Wounds therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Wounds

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Wounds

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AdiSave Inc

Agile Sciences Inc

Aiviva BioPharma Inc

AlgiPharma AS

Allander Biotechnologies LLC

Alliance Pharma Plc

AMNICELL Corp Ltd

Ankasa Regenerative Therapeutics Inc

Apidel SA

Aposcience AG

Araim Pharmaceuticals Inc

Arava Bio-Tech Ltd

Armata Pharmaceuticals Inc

Arrevus Inc

Auxagen Inc

Avalon GloboCare Corp

Axolo Pharma Inc

Biomendics LLC

Biotec Pharmacon ASA

Canton Biotechnologies Inc

CarthroniX Inc

Cellphire Inc

Clene Nanomedicine Inc

Crioestaminal Saude e Tecnologia SA

Daewoong Pharmaceutical Co Ltd

Destiny Pharma Plc

Exicure Inc

Exopharm Ltd

EyeGene Inc

Factor Therapeutics Ltd

FortuneRock (China) Ltd

Gene Signal International SA

Helixmith Co Ltd

Histogen Inc

Huons Global Co Ltd

Ilya Pharma AB

Krystal Biotech Inc

LayerBio Inc

Lipid Biologics LLC

Living Cell Technologies Ltd

Madam Therapeutics BV

MangoGen Pharma Inc

Marizyme Inc

MediaPharma SRL

MediWound Ltd

MicroCures Inc

Miragen Therapeutics Inc

NellOne Therapeutics Inc

Novion Technologies Inc

Novopyxis Inc

Omeros Corp

Opal Biosciences Ltd

Pacific Northwest Biotechnology LLC

PhagoMed Biopharma GmbH

Phoenicia Biosciences Inc

QBiotics Ltd

Regeneus Ltd

Remedor Biomed Ltd

Reponex Pharmaceuticals Aps

Resolys Bio Inc

Reven Pharmaceuticals Inc

Revive Therapeutics Ltd

Riptide Bioscience Inc

Scarless Laboratories Inc

SomaGenics Inc

Synedgen Inc

TGV-Inhalonix Inc

Thesan Pharmaceuticals Inc

Topadur Pharma AG

Transwell Biotech Co Ltd

Traverse Biosciences Inc

Tumorend LLC

Valitor Inc

Vascular BioSciences

Vasomune Inc

viDA Therapeutics Inc

Yabao Pharmaceutical Group Co Ltd

Zih Yuan Tang Biotechnology Co Ltd

ZZ Biotech LLC

Table of Contents

Table of Contents

Introduction

Wounds - Overview

Wounds - Therapeutics Development

Wounds - Therapeutics Assessment

Wounds - Companies Involved in Therapeutics Development

Wounds - Drug Profiles

Wounds - Dormant Projects

Wounds - Discontinued Products

Wounds - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Wounds, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Wounds – Pipeline by AdiSave Inc, H1 2020

Wounds – Pipeline by Agile Sciences Inc, H1 2020

Wounds – Pipeline by Aiviva BioPharma Inc, H1 2020

Wounds – Pipeline by AlgiPharma AS, H1 2020

Wounds – Pipeline by Allander Biotechnologies LLC, H1 2020

Wounds – Pipeline by Alliance Pharma Plc, H1 2020

Wounds – Pipeline by AMNICELL Corp Ltd, H1 2020

Wounds – Pipeline by Ankasa Regenerative Therapeutics Inc, H1 2020

Wounds – Pipeline by Apidel SA, H1 2020

Wounds – Pipeline by Aposcience AG, H1 2020

Wounds – Pipeline by Araim Pharmaceuticals Inc, H1 2020

Wounds – Pipeline by Arava Bio-Tech Ltd, H1 2020

Wounds – Pipeline by Armata Pharmaceuticals Inc, H1 2020

Wounds – Pipeline by Arrevus Inc, H1 2020

Wounds – Pipeline by Auxagen Inc, H1 2020

Wounds – Pipeline by Avalon GloboCare Corp, H1 2020

Wounds – Pipeline by Axolo Pharma Inc, H1 2020

Wounds – Pipeline by ZZ Biotech LLC, H1 2020

Wounds – Dormant Projects, H1 2020

Wounds – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Wounds, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports